Part I: EchoNext Clears FDA for Six Structural Heart Conditions Off a Standard ECG, Lands on OpenEvidence, and Logs the First AI-Triggered Heart Transplant: Reading the Cardiac Screening Land Grab
By
Thoughts on Healthcare
7d agoen
Source
Pathway Labs cleared the FDA for six structural heart conditions off one ECG.
You might also wanna read
FDA Clears EchoNext, First AI Tool to Detect Structural Heart Disease from ECGs Before Symptoms Appear
The FDA has cleared EchoNext, a first-of-its-kind artificial intelligence tool developed by Pathway Labs that reads standard electrocardiogr
iCardio.ai Launches FDA-Cleared AI Platform for Automated Echocardiography Analysis
iCardio.ai is an AI-powered platform that helps ultrasound teams automate echocardiography measurements, detect aortic stenosis, and generat
A very impressive discovery of a new ECG marker for sudden cardiac death validated in 3 different cohorts and linked to benefit of defibrillator, an outgrowth of human research ingenuity and AI deep l
nature.com·13d ago
A very impressive discovery of a new ECG marker for sudden cardiac death validated in 3 different cohorts and linked to benefit of defibrillator, an outgrowth of human research ingenuity and AI deep l
nature.com·13d ago
A very impressive discovery of a new ECG marker for sudden cardiac death validated in 3 different cohorts and linked to benefit of defibrillator, an outgrowth of human research ingenuity and AI deep l
nature.com·13d ago

My father is a cardiologist.
SOND·1mo ago
AI-powered stethoscope shows promise for rapid detection of heart conditions, study finds
A British research team has conducted a study showing that AI-powered stethoscopes can detect three heart conditions — heart failure, heart
AI model trained on routine ECGs detects hidden patterns linked to sudden cardiac death risk, UC Berkeley study finds
UC Berkeley researchers have developed an AI model trained on routine ECGs that can detect hidden patterns associated with sudden cardiac de

Comments
Sign in to join the conversation.
No comments yet. Be the first.